TrioBiotics Pharma AG
Triton BioPharma AG submits Grant Application to U.S. Department of Defense’s Congressionally Directed Medical Research Program regarding Traumatic Brain Injury Research
Triton Biopharma AG / Miscellaneous/Strategic Company Decision Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- ZUG, Switzerland – January 28th, 2009 – TRITON BIOPHARMA AG (Frankfurt: 4ON) announced today that its wholly-owned R&D subsidiary company, Triton BioPharma LLC, has submitted a grant proposal to the U.S. Department of Defense’s Congressionally Directed Medical Research Program (CDMRP). Triton targets the preclinical development of novel anti-inflammatory agents derived from marine sources to provide near and long-term benefits in soldiers with traumatic brain injury (TBI) by preventing tissue damage and neurodegeneration associated with inflammation. This Deployment Related Medical Research Program funding opportunity is for an Advanced Technology/Therapeutic Development Award of up to $5 million per year, for a total potential award of $25 million over five years. In response to the request for applications, Triton’s proposal addresses the need for innovative therapies for TBI as military personnel are frequently exposed to blast during combat resulting in head trauma. Investigators participating in the proposed project include key collaborations with researchers of the University of Pennsylvania, Midwestern University, University of Mississippi, Gadjah Mada University and Southern Illinois University. Several thousand novel compounds have been isolated from marine invertebrates, algae, and microorganisms, many of which have shown anti-inflammatory activity as reviewed by the investigative team. This group has contributed for over 20 years to the preclinical in vitro and in vivo anti-inflammatory pharmacology of the marine compounds manoalide, pseudopterosins and manzamines. It is anticipated that this research will also be significant to non-military persons that have experienced non-combat related head trauma due to a fall, stroke, sports or work-related injury or motor vehicle accident. These compounds may have even broader clinical application in the treatment of neurological disorders involving neurodegeneration such as Parkinson’s disease, multiple sclerosis, and dementias including Alzheimer’s disease. Due to common targets linking immune suppression and inflammation as exemplified by this class of drug leads the toxicology, efficacy and optimization studies proposed as part of this program will also advance a promising class of immunosuppressive agents with possible applications in transplantation and autoimmune diseases. 'Although this research proposal is of importance to military personnel, it should be emphasized this project offers new developments in the areas of Alzheimer’s and Parkinson’s disease', stated Angelo Boujos, President & CEO of Triton BioPharma AG. 'We are very confident in the strength of this preclinical proposal with the expertise and experience of this investigative team in producing and developing novel marine natural product leads.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton’s biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. With a commitment to cooperation in innovation, Triton brings together a significant network of international collaborators, consultants and industry specialists in the areas of microbiology, pharmacology, synthetic and organic chemistry, marine natural products and biochemistry. Accessing this critical mass of scientific experts and utilizing research facilities worldwide is a principal component of its drug discovery and development strategy. Triton’s current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. For more information, visit www.tritonbiopharma.com Investor Relations Europe: Milestone Media AG, Zug (Switzerland) Phone: +41 (0) 41 5000 769 Fax: +41 (0) 41 5000 728 E-mail: info@milestonemedia.ch 28.01.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden